Investigation of the binding specificity of IGF-1R using monoclonal antibodies. by Keyhanfar, Mehrnaz
INVESTIGATION OF 

THE BINDING SPECIFICITY OF IGF-IR 

USING MONOCLONAL ANTIBODIES 

By 
Mehrnaz Keyhanfar, Pharm.D. 
A thesis submitted to the University of Adelaide, South Australia 

in fulfilment of the requirements for the degree of 







School of Molecular and Biomedical Science 

The University of Adelaide 






The insulin-like growth factor type one receptor (IGF-IR) plays a critical role in cancer. The 
receptor is over expressed in many tumours and mediates growth, motility, and survival from 
apoptosis. Several studies have shown that the inhibition of IGF- l R's expression or its 
function blocks tumour growth or metastasis, and also enhances sensitivity to cytotoxic drugs 
and irradiation. To date, IGF-IR is widely considered as a very promising target for cancer 
treatment. 
Among different techniques for targeting IGF-IR, blocking the receptor with specific 
monoclonal antibodies (MAbs) is an attractive way to inhibit the receptor signalling. In 
addition, antibodies specific for the IGF-IR are potential diagnostic reagents as the IGF-IR is 
overexpressed in several cancers. A similar approach has been successfully utilized in the 
treatment of breast cancer using Herceptin, which is a humanised MAb against human 
epidermal growth factor receptor-2. 
In this thesis, two high affinity murine MAbs against IGF-IR namely 7C2 and 9El l 
were isolated and cloned. To obtain these MAbs, s-IGF-IR (the soluble extracellular part of 
the IGF-IR, amino acids 1-906) was used as an\mmunogen. These MAbs were IgGIK 
isotype and did not cross react with either insulin receptor isoform IR-A or IR-B. MAbs 7C2 
and 9Ell successfully detected IGF-IR in a number of immunoassays such as in enzyme 
linked immunosorbent assays (ELISAs), flow cytometry and immunohistochemistry. The 
MAbs also immunoprecipitated IGF-IR from lysates of cells overexpressing recombinant 
IGF-IR. Both MAbs 7C2 and 9El l showed high affinity to the s-IGF-IR. The binding 
affinities of the MAbs 7C2 and 9El l to s-IGF-IR were 0.5±1.6 nM and 2.1±0.4 nM, 
respectively. The sequences of the variable regions of these MAbs' heavy and light chains 
were also described in this study. Comparison of the CDR sequences of the MAbs with those 
of other MAbs against the IGF-IR showed that MAbs 7C2 and 9El l each had a unique 
sequence. 
II Abstract 
During this research it was found that MAbs 7C2 and 9El l blocked the binding of 
IGF-I to the IGF-IR. but did not show an inhibitory effect on the binding of IGF-I1 to this 
receptor. Moreover, epitope mapping of MAbs 7C2 and 9El l revealed that they both bound 
to the cysteine-rich domain of the receptor. These fmdings support a previous study, which 
demonstrated that the cysteine-rich domain oflGF-l R is critical for specific binding oflGF-I 
but not IGF-I1 to the receptor. 
In this thesis, further epitope mapping studies on MAbs 7C2 and 9El l using alanine 
mutants of the IGF-IR in the cysteine-rich domain are reported. The results showed that 
amino acids F241, F251 and F266 were involved in binding to both MAbs 7C2 and 9EII. On 
the other hand, another study showed that amino acids F241 and F251 were crucial for IGF-I 
binding to the receptor. Therefore, binding to these two amino acids by MAbs 7C2 and 9EI l 
is most likely responsible for the selective blocking of IGF-I but not IGF-I1 to the receptor. 
Competition experiments performed during this research revealed that the chimeric 
IGF analogues IGF-ICII (IGF-I with IGF-II C domain) and IGF-IICI (IGF-II with IGF-I C 
domain) behaved like IGF-II and IGF-I. respectively in their ability to inhibit the binding of 
MAbs 7C2 and 9EIl to s-IGF-IR. These findings imply that out of all four domains of IGF-I, 
" 
it is the C domain, which binds to residues in IGF-IR that form the epitope for MAbs 7C2 
and 9El l .  Because in the C domain of IGF-I, amino acids R36 and R37 and also Y31 have 
been shown to be important for binding to IGF-IR, it could be proposed that the binding of 
the IGF-I C domain to the IGF-IR cysteine-rich domain is through binding amino acids R36, 
R37 and Y31 of IGF-I to residues F241 and F251, or to the nearby residues, which are 
sterically affected by the presence of the MAbs binding to the receptor. 
In this research, in vitro studies, using MAbs as anti-cancer reagents revealed that both 
MAbs 7C2 and 9E 11 inhibited the proliferation of colon cancer cell (HT -29) induced by 
IGF-I and IGF-IL However, the neutralizing effect for IGF-I1 was less potent than for IGF-L 
Since the MAbs did not inhibit binding of IGF-II to the receptor, their effect on IGF-II 
induced cell proliferation could be claimed to be due to an indirect effect. This is consistent 
Abstract III 
with the in vitro result for the receptor down-regulation experiment. which showed that 24 h 
incubation of breast cancer cells (MCF-7) with MAbs 7C2 and 9El l ,  significantly reduced 
the IGF-IR expression. In this study it was also shown that MAbs 7C2 and 9El l inhibited 
MCF-7 cells migration induced by IGF-1. This could indicate a potential anti-metastatic 
property ofMAbs 7C2 and 9El l. 
Taken together, the in vitro effects of MAbs 7C2 and 9E 11 reported in this thesis 
revealed that they had inhibiting effects on cancer cell proliferation and migration and they 
also induced IGF-lR down-regulation. Therefore, they could be potentially valuable prospects 
for cancer treatment if humanised. 
Finally, MAbs 7C2 and 9El l could be used as diagnostic reagents to detect IGF-IR in 
cells or tissue samples in a range of immunoassays as mentioned earlier. Due to the IGF-lR 
overexpression in several cancer tumours, MAbs 7C2 and 9E I I  could be utilized for 
malignant tumour recognition. Furthermore, as another application, these MAbs could also be 
used to identify tumours overexpressing the IGF-lR, allowing tailored anti-cancer treatment 
including an IGF-IR blocking agent. 
" 
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